CY1112637T1 - Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινης - Google Patents
Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινηςInfo
- Publication number
- CY1112637T1 CY1112637T1 CY20121100272T CY121100272T CY1112637T1 CY 1112637 T1 CY1112637 T1 CY 1112637T1 CY 20121100272 T CY20121100272 T CY 20121100272T CY 121100272 T CY121100272 T CY 121100272T CY 1112637 T1 CY1112637 T1 CY 1112637T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pyrazolopyrimidine derivative
- present
- prevention
- treatment
- diseases containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με φαρμακευτική σύνθεση για την πρόληψη και αγωγή των παθήσεων του ήπατος περιέχουσα παράγωγο πυραζολοπυριμιδίνης ως δραστικό συστατικό. Σύμφωνα με την παρούσα εφεύρεση, το παράγωγο πυραζολοπυριμιδίνης έχει εξαιρετική επίδραση στην αναστολή της σύνθεσης του κολλαγόνου σε ηπατικά αστεροειδή κύτταρα και δρα άμεσα στην πυλαία φλέβα. Ειδικότερα δε, αυτό μπορεί να αυξήσει την διάμετρο και την ποσότητα της ροής του αίματος της πυλαίας φλέβας, και να μειώσει τελικώς την πίεση εξ' αυτής. Επομένως, το παράγωγο πυραζολοπυριμιδίνης μπορεί να χρησιμοποιηθεί πλεονεκτικώς για την πρόληψη και αγωγή της ηπατικής ίνωσης, της κίρρωσης του ήπατος που προκαλείται από ηπατική ίνωση, της πυλαίας υπέρτασης και διαφόρων επιπλοκών που προκαλούνται από πυλαία υπέρταση. Επιπλέον, το παράγωγο πυραζολοπυριμιδίνης σύμφωνα με την παρούσα εφεύρεση μπορεί να μειώσει την συχνότητα δοσολόγησης λόγω της μακράς ημι-περιόδου ζωής αυτού, και επομένως έχει πλεονέκτημα στην βελτίωση της συμμόρφωσης των ασθενών στο φάρμακο που υποφέρουν από χρόνιες παθήσεις του ήπατος.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20050050033 | 2005-06-10 | ||
EP05808627A EP1888074B1 (en) | 2005-06-10 | 2005-10-21 | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112637T1 true CY1112637T1 (el) | 2016-02-10 |
Family
ID=37498629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100272T CY1112637T1 (el) | 2005-06-10 | 2012-03-14 | Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινης |
Country Status (22)
Country | Link |
---|---|
US (1) | US8796286B2 (el) |
EP (1) | EP1888074B1 (el) |
JP (1) | JP4879977B2 (el) |
KR (1) | KR100914445B1 (el) |
CN (1) | CN101193636B (el) |
AT (1) | ATE537832T1 (el) |
AU (1) | AU2005332719B2 (el) |
BR (1) | BRPI0520209A2 (el) |
CA (1) | CA2611638C (el) |
CY (1) | CY1112637T1 (el) |
DK (1) | DK1888074T3 (el) |
ES (1) | ES2376628T3 (el) |
HK (1) | HK1119596A1 (el) |
IL (1) | IL187678A (el) |
MX (1) | MX2007015365A (el) |
NO (1) | NO20076053L (el) |
NZ (1) | NZ564369A (el) |
PT (1) | PT1888074E (el) |
RU (1) | RU2369392C2 (el) |
UA (1) | UA86528C2 (el) |
WO (1) | WO2006132460A1 (el) |
ZA (1) | ZA200800180B (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2101809B1 (en) * | 2006-12-28 | 2011-10-19 | Insect Biotech Co., Ltd. | Pharmaceutical composition containing arazyme for the prevention of liver dysfunction |
WO2010118367A2 (en) * | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
AU2011279144A1 (en) * | 2010-07-14 | 2013-01-24 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists |
JP6235583B2 (ja) * | 2012-07-11 | 2017-11-22 | ユニバーシティー オブ ミシシッピ メディカル センター | 画像獲得データから肝線維症を検出及びステージ決定する方法 |
AU2015258805B2 (en) | 2014-05-16 | 2018-05-10 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
JP7033454B2 (ja) | 2015-06-30 | 2022-03-10 | カンバーランド ファーマシューティカルズ,インコーポレーテッド | Aerd/喘息におけるトロンボキサン受容体拮抗薬 |
ES2955158T3 (es) | 2016-05-11 | 2023-11-29 | Cumberland Pharmaceuticals Inc | Composiciones y métodos de tratamiento de la distrofia muscular con antagonistas del receptor de tromboxano-A2 |
CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
AU2022325803A1 (en) * | 2021-08-13 | 2024-03-28 | Goldberg, David J. | Methods and compositions for treating fibrotic liver conditions, using udenafil compositions |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100353014B1 (ko) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
KR100377782B1 (ko) | 2000-06-23 | 2003-03-29 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법 |
US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
GB0202254D0 (en) * | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
AU2003286555A1 (en) | 2002-10-22 | 2004-05-13 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases |
WO2004108662A1 (ja) | 2003-05-15 | 2004-12-16 | Kumiai Chemical Industry Co., Ltd. | フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤 |
DE10325813B4 (de) | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
CA2528975A1 (en) * | 2003-06-10 | 2004-12-16 | Pfizer Inc. | Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea |
DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
-
2005
- 2005-10-21 WO PCT/KR2005/003526 patent/WO2006132460A1/en active Application Filing
- 2005-10-21 BR BRPI0520209-4A patent/BRPI0520209A2/pt not_active IP Right Cessation
- 2005-10-21 CA CA2611638A patent/CA2611638C/en not_active Expired - Fee Related
- 2005-10-21 RU RU2007149474/15A patent/RU2369392C2/ru active
- 2005-10-21 AT AT05808627T patent/ATE537832T1/de active
- 2005-10-21 KR KR1020050099900A patent/KR100914445B1/ko active IP Right Grant
- 2005-10-21 CN CN2005800500656A patent/CN101193636B/zh not_active Expired - Fee Related
- 2005-10-21 JP JP2008515614A patent/JP4879977B2/ja not_active Expired - Fee Related
- 2005-10-21 EP EP05808627A patent/EP1888074B1/en active Active
- 2005-10-21 US US11/916,752 patent/US8796286B2/en active Active
- 2005-10-21 DK DK05808627.3T patent/DK1888074T3/da active
- 2005-10-21 MX MX2007015365A patent/MX2007015365A/es active IP Right Grant
- 2005-10-21 ES ES05808627T patent/ES2376628T3/es active Active
- 2005-10-21 UA UAA200713931A patent/UA86528C2/uk unknown
- 2005-10-21 AU AU2005332719A patent/AU2005332719B2/en not_active Ceased
- 2005-10-21 PT PT05808627T patent/PT1888074E/pt unknown
- 2005-10-21 NZ NZ564369A patent/NZ564369A/en not_active IP Right Cessation
-
2007
- 2007-11-26 NO NO20076053A patent/NO20076053L/no not_active Application Discontinuation
- 2007-11-27 IL IL187678A patent/IL187678A/en not_active IP Right Cessation
-
2008
- 2008-01-08 ZA ZA200800180A patent/ZA200800180B/xx unknown
- 2008-11-27 HK HK08112976.5A patent/HK1119596A1/xx not_active IP Right Cessation
-
2012
- 2012-03-14 CY CY20121100272T patent/CY1112637T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2611638C (en) | 2010-08-24 |
WO2006132460A1 (en) | 2006-12-14 |
JP2008543748A (ja) | 2008-12-04 |
CA2611638A1 (en) | 2006-12-14 |
PT1888074E (pt) | 2012-03-01 |
CN101193636A (zh) | 2008-06-04 |
US8796286B2 (en) | 2014-08-05 |
RU2007149474A (ru) | 2009-07-20 |
US20080207646A1 (en) | 2008-08-28 |
UA86528C2 (uk) | 2009-04-27 |
EP1888074B1 (en) | 2011-12-21 |
KR20060128605A (ko) | 2006-12-14 |
EP1888074A4 (en) | 2010-06-23 |
KR100914445B1 (ko) | 2009-08-28 |
MX2007015365A (es) | 2008-02-12 |
DK1888074T3 (da) | 2012-01-23 |
NO20076053L (no) | 2008-02-27 |
JP4879977B2 (ja) | 2012-02-22 |
RU2369392C2 (ru) | 2009-10-10 |
HK1119596A1 (en) | 2009-03-13 |
ZA200800180B (en) | 2009-01-28 |
AU2005332719B2 (en) | 2010-05-13 |
BRPI0520209A2 (pt) | 2009-04-22 |
CN101193636B (zh) | 2011-12-28 |
ATE537832T1 (de) | 2012-01-15 |
EP1888074A1 (en) | 2008-02-20 |
AU2005332719A1 (en) | 2006-12-14 |
IL187678A (en) | 2013-04-30 |
NZ564369A (en) | 2010-03-26 |
IL187678A0 (en) | 2008-11-03 |
ES2376628T3 (es) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112637T1 (el) | Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινης | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
NO20075136L (no) | Nye liposompreparater | |
EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
EA200501570A1 (ru) | Новые гидроксаматы как лечебные средства | |
BRPI0513455A (pt) | formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada | |
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
WO2005075471A3 (en) | Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
NO20074109L (no) | Intravenose formuleringer av PDE-5 inhibitorer | |
EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
MX2009011900A (es) | Curacion de herida diabetica. | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
CY1112191T1 (el) | Παραγωγο πυραζολοπυριμιδινης | |
WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
WO2006125194A3 (en) | Piperazine derivatives and their uses as therapeutic agents | |
MXPA05010020A (es) | Derivados de oxamida. | |
WO2001062799A3 (en) | Method for inhibiting angiogenesis using molecules that enhance plasmin activity | |
NO20064298L (no) | Piperazinureaderivater til behandling av endometriose | |
SE0203817D0 (sv) | New composition | |
MY148300A (en) | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative | |
WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption |